CALR and myeloproliferative neoplasm: As opposed to the prothrombotic influence of JAK2 mutations, CALR and MPL driver mutations are reported with very low to almost absent prevalence in MPN-SVT (0.01–0.06% for MPL, 1–5% for CALR) [22,25,35,79].